This keystone symposium will focus on advances in the rapidly evolving fields of targeted protein degradation and chemically-induced proximity. In recent years, there has been a major acceleration in the translation of targeted protein degraders from basic research studies into clinical trials, bringing with it the need to better understand and predict the clinical pharmacology of targeted protein degradation. Through the sharing of these results, the field will continue to gain momentum in bringing advances in TPD to patients.

In parallel, a resurgence of interest in induced proximity has fostered the creation of modalities that hijack other cellular processes, including autophagy, endocytosis, immune signaling, protein chaperones, and transcription. The scope of application, and the therapeutic potential, of these approaches is still emerging, and this meeting will provide a forum to bring together subject matter experts across disciplines, to foster new collaborations in these fledgling scientific areas.

This meeting will bring together experts across diverse disciplines, working at each stage of the TPD and induced proximity field, from new technology development to clinical implementation.

Meeting organizers, Dr. Philip Chamberlain and Dr. Fleur Ferguson, talk about why you should attend this meeting in the video below: